Show Menu
Cheatography
  1. Home >
  2. Cheat Sheets >

RCC, 2nd Line Cheat Sheet (DRAFT) by

RCC data

This is a draft cheat sheet. It is a work in progress and is not finished yet.

Checkmate 025

OS*
25 vs 19.6 mo
HR .7 p+0.0018
ORR confirmed
21.5 v 3.9%
>0.001
Duration of Response
23 vs 13.7 mo
Med time to response
3.0 vs 3.7 mo
Motzer NEJM 2015
Nivolumab vs everolimus

AXIS Inlyta (axitinib) vs Sorafanib

PFS*
6.7 vs 4.7 mo
HR .665 p>0.0001
ORR
19.4 vs 9.4%
HR.74
OS
20.1 vs 19.2 mo
HR.97 p=.37
AXIS axitinib vs sorafanib Ph 3 Motzer­/Rini Lnacet Onc 2013
n=723 35% prior sunitinib, 35% cytokine, 8% bev, 3% temsir­olimus
Sunitinib refractory PFS 4.8 vs 3.4 mo HR.74
Cytokine refractory PFS 12.1 vs 6.5mo
DC due to AE's 4%
Ph 2 cytokine refractory 5 yr survivial 20.6% with 5.9 yr FU
  

METEOR

PFS*
7.4 vs 3.8 mo
HR 0.58 p>0.0001
ORR
21 vs 5%
p> 0.001
OS
21.4 vs 16.5 mo
HR.66 p=0.0003
Choueiri NEJM 2015
n=658 Caboza­ntanib 60mg vs everolimus 10mg
69% had only 1 line of previous therapy
MSKCC 46% favorable, 42% interm­ediate, 13% poor
Confirmed ORR (PR only) 17 vs 3% p>0.0001
  

Lenvim­a+E­ver­olimus

PFS*
14.6 vs 5.5 mo
HR.37
mOS
25.5 vs 15.4 mo
HR.67
ORR
19 vs 3%
p<0.001
ASCO 2015
n=153
major toxicity Diarrhea, fatigue, renal failure, HTN,
89% dose reduction, 29% DC

Keynote

Os
No met
Who cated
oD
Ghj
Happy

Bevaci­zumab vs placebo

PFS* 10mg
  
HR 2.55 p<0.001
PFS 3 mg
  
HR 1.26 p=0.053
bevaci­zumab vs Placebo NEJM 2003 Yang
bev 3 or 10mg
NCCN Cat 2B after TKI